Epitan receives marketing approval for Zindaclin

By Ruth Beran
Tuesday, 08 November, 2005

Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has received approval from the Therapeutic Goods Administration (TGA) for the registration of anti-acne treatment Zindaclin.

Zindaclin is a once-a-day clindamycin-based gel which Epitan's wholly-owned subsidiary Epipharm in-licensed from UK-based Pro-Strakan Pharmaceuticals (formerly Strakan) in July 2004. The product was submitted for registration from the TGA soon after.

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Content from other channels on our network

Air-gapped networks give a false sense of security

BHP strengthens partnership with ABB

Seamless modular I/O integration

Coca-Cola invests nearly $100 million in Queensland manufacturing

Endress+Hauser receives IEC 62443‍-‍4‍-‍1 cybersecurity certification

Orica cuts particle emissions from Kooragang Island site by around 95%

CSIRO's new facility for printed flexible solar techology

Driving change: how electric vehicles are fuelling Australia's sustainable businesses

CSIRO gathers innovators to tackle plastic waste

Trinasolar launches agrivoltaics project in NZ

Review proposes major health system changes

Private Health CEO Forum to tackle financial viability issues

Medline introduces Namic Ready Set Kits

Solventum innovations enabling better, smarter, safer healthcare

Lumia Care expands national network with SA acquisition